## Language

### Beneficial effects of pharmacological treatment in post-stroke dynamic aphasia: a behavioural and neuroimaging study

Diana López-Barroso, María José Torres-Prioris, Álvaro Beltrán-Corbellini, Nuria Roé-Vellvé, José Paredes-Pacheco, Lisa Edelkraut, Guadalupe Dávila, Marcelo Berthier

First author address: University of Malaga, Malaga, Spain. First author email: dlopezbarroso@gmail.com

**Introduction:** Dynamic Aphasia (DA) is a rare form of language disorder characterized by reduced spontaneous speech with preservation of other language functions. Two types of DA have been described: language-specific type (type I DA) and domain-general type (type II DA). In type I DA, deficits are selective for word and sentence generation, whereas in type II DA impairments affect discourse generation, narrative, fluency, and non-verbal generation tasks. There is little information on the treatment of DA. Although treatment with a cognitive enhancing drug (bromocriptine) improved outcome in previous studies, pharmacological interventions combining two drugs acting on other neurotransmitter systems in DA have not been reported so far.

**Methods:** We report an open-label pharmacological single case study (n = 1) in a male patient with a chronic type I/II DA secondary to an ischemic infarction in the left fronto-opercular and insular regions. After baseline evaluation, the patient received donepezil 5 mg/day (2 months), donepezil 10 mg/day (2 months), donepezil 10 mg/day plus memantine 20 mg/day (4½ months) followed by a washout period (1½ months). No speech-language therapy was used. A comprehensive cognitive and language evaluation was carried out at baseline and at different endpoints. 18FDG-PET was performed at the four timepoints.

**Results:** Donepezil (5 mg/day) significantly improved type I DA features (normalization of verbs generation, \( p = 0.01 \)), whereas donepezil (10 mg/day) improved some type II features (normalizing spontaneous speech, verbal fluency and improving generation of novel thoughts, \( p = 0.004 \)), along with improvement of executive-attentional functioning. Combined therapy further enhanced cognitive function, but did not additionally improved DA. 18FDG-PET revealed significant reductions of perilesional hypometabolic activity mainly after donepezil (10 mg/day) and washout.

**Discussion:** Treatment with donepezil improved language deficits in a patient with chronic post-stroke type I/II DA. Combined therapy (donepezil plus memantine) further enhanced executive-attentional functioning. Beneficial changes were associated with improvements in perilesional metabolic activity.


**Keywords:** Language; patients; single case study; adults; cerebrovascular; behavioural, functional imaging.

---

First author: **Are you interested in a Oral presentation during the Small Group evening meetings?**  
No

Are you a PhD student or a Post-Doc?  
No

Unfortunately this abstract has arrived too late for the **EWCN Prize selection.**  
ok

Date of submission: 30/11/2017 22:57:20